石家庄以岭药业股份有限公司 第八届董事会 2025 年第一次独立董事专门会议决议 石家庄以岭药业股份有限公司（以下简称"公司"）第八届董事会 2025 年 第一次独立董事专门会议于 2025 年 4 月 28 日以现场方式召开，应参加会议独立 董事 3 人，实际参加会议独立董事 3 人。会议审议通过了以下议案： 1、审议通过了《关于预计 2025 年度日常关联交易的议案》。 我们认为：（1）公司 2024 年度日常关联交易对公司日常经营及业绩未产生 重大影响，2024 年度关联交易实际发生总额未超过预计总金额，实际发生金额 与预计金额存在差异属于正常的经营行为，符合公司实际经营情况，交易定价公 允、合理，未出现损害公司及全体股东利益，特别是中小股东利益的情形。 （2）公司与各主要关联方的日常关联交易符合公司 2025 年度经营所需要， 且涉及金额占公司同类业务比重较低，对公司的财务状况、经营成果不会构成重 大影响，公司的主营业务不会因此类关联交易而对关联方形成依赖，不会影响公 司的独立性；关联交易定价原则为按市场价格定价，遵循公平、公正、公开的原 则，不存在损害公司和全体股东特别是中小股东利益的行为。 公司本 ...

证券代码：002603 证券简称：以岭药业 公告编号：2025-010 石家庄以岭药业股份有限公司 第八届董事会第十五次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 石家庄以岭药业股份有限公司第八届董事会第十五次会议于 2025 年 4 月 28 日在公司会议室以现场方式召开。本次会议通知和文件于 2025 年 4 月 18 日以电 话通知并电子邮件方式发出。会议应参加表决董事9人，实际参加表决董事9人。 会议由公司董事长吴相君主持，监事会成员、公司高级管理人员列席了会议。本 次会议的召集程序、审议程序和表决方式均符合《公司法》、相关法律法规及本 公司章程的规定。 会议以记名投票表决方式审议通过了以下议案并形成决议如下： 一、审议通过了《2024 年度总经理工作报告》。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 二、审议通过了《2024 年度董事会工作报告》。 表决情况：同意 9 票，反对 0 票，弃权 0 票。 本议案需提请公司股东大会审议。 公司现任独立董事刘骁悍、陈刚、柴振国向董事会提交了独立董事述职报告， 并将在 2024 ...

证券代码：002603 证券简称：以岭药业 公告编号：2025-012 石家庄以岭药业股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 三、利润分配预案的具体情况 （一）公司 2024 年度利润分配预案不触及其他风险警示情形 2 | 项目 | 本年度 | 上年度 | 上上年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 0.00 | 501,211,612.80 | 835,352,688.00 | | 回购注销总额（元） | 0.00 | 0.00 | 0.00 | | | -724,515,582.24 | 1,352,379,242.86 | 2,361,804,714.55 | | 利润（元） | | | | | | | 5,280,359,642.51 | | | 分配利润（元） | | | | | | | 5,060,397,687.83 | | | 未分配利润（元） | | | | | 上市是否满三个完整会 | | 是 | | | 计年度 | | | | ...

Core Viewpoint - Yiling Pharmaceutical reported a significant loss in 2024 due to revenue reduction from near-expiry respiratory products and inventory impairment, but showed improvement in Q1 2025 with a notable increase in net profit and cash flow [1][2][3][4]. Financial Performance - In 2024, the company achieved a total revenue of 6.513 billion yuan, with a net loss of 725 million yuan primarily due to the write-down of near-expiry respiratory products and inventory impairment [1][2]. - For Q1 2025, the company reported a revenue of 2.358 billion yuan and a net profit of 326 million yuan, marking a year-on-year growth of 7.25% [2]. - The net profit attributable to the parent company, after excluding non-recurring items, was 325 million yuan, reflecting an 11.23% increase year-on-year [2]. - The gross margin for Q1 2025 was 53.82%, up by 2.34 percentage points, while the net margin was 13.82%, an increase of 1.85 percentage points [2]. Cash Flow and Receivables - The net cash flow from operating activities for 2024 was 611 million yuan, a year-on-year increase of approximately 293%, with Q4 2024 alone showing a cash flow of 288 million yuan, up over 26 times [3]. - In Q1 2025, the operating cash flow reached 340 million yuan, nearly doubling year-on-year and exceeding the net profit for the same period [3]. - Accounts receivable at the end of 2024 were 1.225 billion yuan, a significant decrease of 50% from the beginning of the year [3]. Debt and Financial Health - Total liabilities at the end of 2024 were 3.117 billion yuan, down by 24.24 billion yuan or 43.75% year-on-year, leading to a reduction in the debt-to-asset ratio by nearly 10 percentage points to 23.4% [3]. R&D Investment - In 2024, the company's R&D investment exceeded 900 million yuan, accounting for 13.9% of total revenue, positioning it as a leader in the industry [5]. - The company expanded its innovative traditional Chinese medicine portfolio to 17 products, covering eight major clinical disease systems, with significant advancements in cardiovascular and respiratory medications [5]. - Several new drugs received approval or acceptance from the National Medical Products Administration, including treatments for allergic rhinitis and gallbladder inflammation [5].

Financial Performance - The company's operating revenue for 2024 was CNY 6,512,734,471.7, a decrease of 36.88% compared to CNY 10,318,312,851 in 2023[14]. - The net profit attributable to shareholders was a loss of CNY 724,515,582.24, representing a decline of 153.57% from a profit of CNY 1,352,379,242.8 in the previous year[14]. - Basic earnings per share were -CNY 0.4337, down 153.58% from CNY 0.8095 in 2023[14]. - Total assets at the end of 2024 were CNY 13,319,171,088, a decrease of 21.56% from CNY 16,979,326,536 in 2023[14]. - The net assets attributable to shareholders decreased by 10.71% to CNY 10,223,487,732 from CNY 11,449,722,316 in 2023[14]. - The company did not distribute any cash dividends or bonus shares for the year 2024[5]. - The company faced significant challenges leading to a substantial decline in both revenue and profit margins compared to previous years[14]. - The management highlighted the need for strategic adjustments to address the current market conditions and improve financial performance moving forward[5]. Cash Flow and Investment - The net cash flow from operating activities increased by 293.04% to CNY 611,013,171.11, compared to CNY 155,457,433.79 in 2023[14]. - The cash flow from operating activities in Q4 2024 was CNY 288.38 million, showing a recovery compared to previous quarters[23]. - The net cash flow from investment activities rose by 279.27% to CNY 1.61 billion, attributed to increased redemption of financial products and reduced investment payments[194]. - The company's investment activities cash outflow decreased by 45.00% to CNY 2.54 billion in 2024, compared to CNY 4.63 billion in 2023[194]. Research and Development - The company is committed to enhancing its research and development efforts to innovate new products and technologies in the pharmaceutical sector[5]. - The company has developed 17 patented traditional Chinese medicines covering 8 major clinical disease systems, with a leading position in the cardiovascular and respiratory disease treatment fields[39]. - The company has received over 400 traditional Chinese medicine invention patents and has won multiple national and provincial scientific and technological awards, including 1 first-class and 4 second-class national scientific and technological progress awards[39]. - The company is focusing on R&D in key disease areas such as cardiovascular, respiratory, and endocrine systems, with multiple projects at various stages of development[130]. - The company has developed over 10 national patent new drugs, covering major diseases such as cardiovascular, respiratory, tumors, diabetes, and neurological disorders, establishing a solid foundation for future growth[110]. Market Position and Strategy - The company is focusing on enhancing its product offerings and expanding its market presence in response to the evolving healthcare landscape in China[34]. - The company has established a comprehensive health industry system integrating medicine, health, and wellness, launching a series of health products including cardiovascular health and anti-aging products[42]. - The company has established a nationwide professional promotion network through partnerships with pharmaceutical distribution enterprises[91]. - The company has formed strategic partnerships with major e-commerce platforms like JD Health and Alibaba Health to enhance its B2B/B2C sales channels[161]. - The company aims to become a leading brand in innovative traditional Chinese medicine and health products through effective media strategies and marketing campaigns[159]. Product Development and Clinical Research - The company has received clinical approval for new drug applications, including Chai Huang Li Dan capsules and Lianhua Yuping granules[130]. - The company is actively conducting ongoing evidence-based medical research on its marketed products, further enhancing their clinical value[116]. - The company has completed multiple post-marketing clinical studies for its products, establishing a solid evidence base for clinical promotion[116]. - The company’s products have undergone randomized, double-blind, multi-center evidence-based medical research, with some results published in international authoritative journals, significantly impacting the medical community[110]. Regulatory and Compliance - The company has obtained 13 ANDA products approved by the US FDA, with one currently under review, and has established agency cooperation with several large US sales companies to continuously enter the US market[146]. - The biopharmaceutical segment aims to achieve compliance with EU and US GMP standards, with successful certification of two factories in Shijiazhuang and Miyun[144]. - The company has registered 14 national standard varieties for formula granules, expanding its prescription field[190]. Awards and Recognition - The company received the 2023 Traditional Chinese Medicine R&D Breakthrough Award in January 2024[173]. - The company was recognized as one of the Top 100 Innovative Pharmaceutical Enterprises in China in September 2024[173]. - The company has received multiple honors, including being listed among China's top 100 innovative brands and top 10 in the pharmaceutical health industry brand value rankings[125]. Challenges and Future Outlook - The company has faced uncertainties regarding its ability to continue as a going concern, as indicated by the negative net profits over the last three accounting years[22]. - The company is actively seeking partnerships in the European market while preparing multiple products for registration[146]. - The company aims to become a large multinational pharmaceutical enterprise with independent intellectual property rights through the development of innovative drugs and international registrations[152].

Financial Performance - The company's revenue for Q1 2025 was ¥2,358,232,707.77, a decrease of 6.52% compared to ¥2,522,632,691.84 in the same period last year[4] - Net profit attributable to shareholders increased by 7.25% to ¥325,953,296.25 from ¥303,927,918.74 year-on-year[4] - Basic and diluted earnings per share rose by 7.26% to ¥0.1951 from ¥0.1819 in the same quarter last year[4] - Total operating revenue for the current period is ¥2,358,232,707.77, a decrease of 6.5% from ¥2,522,632,691.84 in the previous period[18] - Net profit attributable to the parent company increased to ¥325,953,296.25, up 7.0% from ¥303,927,918.74 in the previous period[20] - The total comprehensive income for the current period is ¥324,101,020.55, compared to ¥301,886,529.06 in the previous period[20] Cash Flow - The net cash flow from operating activities surged by 190.67% to ¥340,097,107.41, compared to ¥117,005,271.96 in the previous year[4] - Cash generated from operating activities increased to ¥2,035,275,225.73, up from ¥1,936,876,740.92 in the previous period[22] - Cash inflow from operating activities totaled $2,180,849,648.91, compared to $1,991,079,544.74 in the previous year, reflecting a year-over-year increase[23] - Cash outflow from operating activities was $1,840,752,541.50, slightly decreased from $1,874,074,272.78[23] - The company reported a net exchange loss of ¥54,894.21 in other comprehensive income, compared to a loss of ¥33,169.55 in the previous period[20] - The impact of exchange rate changes on cash and cash equivalents was positive, contributing $81,373.65 to the total[23] Assets and Liabilities - Total assets increased by 2.81% to ¥13,694,088,012.80 from ¥13,319,171,088.28 at the end of the previous year[4] - The company's equity attributable to shareholders grew by 3.19% to ¥10,549,386,134.31 from ¥10,223,487,732.27 at the end of last year[4] - Total liabilities increased to ¥3,167,894,326.54, compared to ¥3,117,078,422.57 in the previous period[16] - Non-current liabilities decreased slightly to ¥506,741,246.93 from ¥510,389,530.41 in the previous period[16] - The total liabilities include accounts payable of ¥1,766,550,464.18, down from ¥1,846,575,493.59, a decrease of approximately 4.3%[15] Shareholder Information - The total number of common shareholders at the end of the reporting period is 185,292[11] - The largest shareholder, Yiling Pharmaceutical Technology Co., Ltd., holds 31.53% of shares, totaling 526,775,963 shares[11] - The second-largest shareholder, Wu Xiangjun, holds 20.81% with 347,728,119 shares, of which 260,796,089 shares are pledged[11] Inventory and Receivables - Accounts receivable increased by 31.17% to ¥1,607,442,791.61, primarily due to increased sales volume[8] - Inventory decreased to ¥1,385,508,236.24 from ¥1,746,380,345.14, reflecting a decline of approximately 20.7%[15] - Accounts receivable rose to ¥1,607,442,791.61 from ¥1,225,430,236.42, indicating an increase of about 31.1%[15] Investment Activities - The company experienced a 356.62% decline in cash flow from investing activities, resulting in a net outflow of ¥198,379,807.59, primarily due to reduced redemptions of financial products[9] - Total cash inflow from investment activities decreased to $280,127,334.14 from $1,481,130,024.34, indicating a decline in investment returns[23] - Cash received from investment recoveries was $280,000,000.00, a significant drop from $1,467,775,784.74 in the previous year[23] - Cash paid for investments was $439,800,000.00, down from $1,341,000,000.00, indicating reduced capital expenditures[23] Operational Insights - The company has ongoing development expenditures of ¥270,129,783.30, up from ¥262,797,369.23, showing an increase of about 2.4%[15] - The company has not reported any new product launches or significant market expansion strategies in the current quarter[13] - The company's cash flow management reflects a strategic focus on improving operational efficiency while navigating investment challenges[23]

证券代码：002603 证券简称：以岭药业 公告编号：2025-007 石家庄以岭药业股份有限公司 关于收到化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，石家庄以岭药业股份有限公司（以下简称"公司"）全资孙公司万洋 衡水制药有限公司（以下简称"衡水万洋"）收到国家药品监督管理局下发的《化 学原料药上市申请批准通知书》，由衡水万洋提交的"来曲唑"化学原料药上市 申请已获批准。现就相关事项公告如下： 截止目前，公司来曲唑原料药累计研发投入约 470 万元，涵盖工艺开发、质 量研究、稳定性研究及注册申报等环节。 申请事项：境内生产化学原料药上市申请 一、批准通知书基本内容 化学原料药名称：来曲唑 登记号：Y20230001258 生产企业名称：万洋衡水制药有限公司 主要结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准注册。质量标准、生产工艺及标签照所附执行。 二、药品的基本情况 化学原料药英文名/拉丁名：Letrozole 来曲唑（Letrozole）是一种高效、选择性非甾体类芳 ...

Group 1 - The company Yiling Pharmaceutical (002603) announced that its wholly-owned subsidiary, Wanyang Hengshui Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the listing application of the chemical raw material drug Letrozole [1] - Letrozole is a highly effective, selective non-steroidal aromatase inhibitor used in the treatment of breast cancer [1] - The global breast cancer drug market is expected to reach USD 37.6 billion by 2025 and between USD 45 billion to USD 55 billion by 2030 [1] Group 2 - The incidence of breast cancer in China is rising annually, leading to an expected continuous growth in the demand for raw materials [1] - The company has invested approximately CNY 4.7 million in the research and development of Letrozole raw materials [1] - The approval enriches the company's product line and helps to expand its business scope, although it is not expected to have a significant impact on performance at this time [1]

石家庄以岭药业股份有限公司 关于提前归还部分补充流动资金的募集资金的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码：002603 证券简称：以岭药业 公告编号：2025-006 石家庄以岭药业股份有限公司（以下简称"公司"）于 2024 年 7 月 8 日分别 召开第八届董事会第十二次会议和第八届监事会第七次会议，审议通过了《关于 使用部分闲置非公开发行募集资金暂时补充流动资金的议案》，决定使用 2017 年 非公开发行募集资金项目部分闲置资金不超过人民币 39,000 万元暂时补充流动 资金，使用期限为自董事会批准之日起不超过 12 个月。相关公告详见刊登于 2023 年 7 月 8 日《中国证券报》《上海证券报》《证券时报》《证券日报》和巨潮资讯 网(www.cninfo.com.cn) 的《关于使用部分闲置非公开发行募集资金暂时补充流 动资金的公告》（公告编号 2024-024）。 2025 年 4 月 24 日，公司将上述用于暂时补充流动资金的募集资金人民币 22,000 万元提前归还至对应募集资金专户。剩余未归还的暂时补充流动资金的募 ...

胡润研究院于4月16日正式发布《2024胡润品牌榜》，评选出中国300强最具价值品牌。其中，以岭药业（002603）凭借其卓越的品牌影响力和市场表现，成 功跻身"地区最具价值品牌前三名"，并荣登医疗健康品牌价值TOP10，再次彰显了其在医药健康行业的领军地位。 作为中国品牌价值100强企业，以岭药业始终坚持"市场龙头，科技驱动"的创新发展战略，构建了"理论-临床-科研-产业-教学"五位一体的运营模式，形成了 涵盖专利中药、化生药、健康产业三大业务板块的产业格局。以岭药业在科技创新领域的成就尤为突出，荣获6项国家科技大奖，其中"中医脉络学说构建及 其指导微血管病变防治"荣获2019年度国家科技进步一等奖，这是年度生命科学领域唯一一项一等奖。 近两年，国家重点研发计划"脉络学说营卫理论指导系统干预心血管事件链研究"取得重大突破，相关成果入选2024世界传统医药大会标志性案例，并获中国 中西医结合学会科学技术一等奖。尤其值得一提的是，该项目子课题通心络胶囊治疗急性心梗相关研究成果登上《美国医学会杂志》(JAMA)，成为中医药 国际化进程中的里程碑事件。此外，连花清瘟胶囊、通心络胶囊等专利产品不仅在国内市场广受认可， ...